MEDARTIS

Medartis's mission is to provide innovative, precision-engineered implant and instrument solutions that support surgeons in achieving optimal patient outcomes, encapsulated in its 'back2fun, back2focus, back2joy, back2play' ethos. The company has demonstrated strong commercial execution, reporting CHF 269.3 million in 2025 sales with 15.7% organic growth and a core EBITDA margin exceeding 18%. Its strategy is built on three pillars: expanding its core CMF and Extremities portfolios, scaling its high-margin CMX patient-specific service, and leveraging the digital Medartis ONE platform to deepen customer engagement and drive operational efficiency.

Precision engineering of titanium/polymer osteosynthesis implant systems and instruments, augmented by a digital CMX service for patient-specific implants and the Medartis ONE knowledge platform.

Medartis competes against large diversified players (e.g., DePuy Synthes, Stryker) and specialized firms in CMF/extremities. Its advantages are Swiss precision engineering, complete system solutions, a direct sales model in key markets, and its differentiated CMX patient-specific service.